Using AI to Improve Treatment for Gliomas
Development of an Artificial Intelligence Model for Optimising Therapy in Gliomas
This study is testing whether using artificial intelligence to analyze genetic data from patients with gliomas can help find more effective treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 164 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centro di Riferimento Oncologico - Aviano Academic / other |
| Locations | 3 sites (Aviano, Pordenone and 2 other locations) |
| Trial ID | NCT06620055 on ClinicalTrials.gov |
What this trial studies
This study aims to utilize artificial intelligence algorithms to analyze genomic data from patients with gliomas, a type of brain tumor. By assessing molecular alterations, the study seeks to determine the percentage of these alterations that are potentially treatable with existing drug therapies. The approach involves comparing results derived from AI analysis with traditional literature data that does not incorporate AI. The goal is to enhance the understanding of glioma treatment options through advanced predictive methods.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of glioma and sufficient biological material for analysis.
Not a fit: Patients who have other neoplastic diseases within the last five years or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective treatment strategies for patients with gliomas by identifying targeted therapies based on molecular characteristics.
How similar studies have performed: While the use of AI in medical research is growing, this specific application in glioma therapy optimization is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with a histopathological diagnosis of glioma for whom it is possible to have cryopreserved or fixed in formalin and embedded in paraffin biological material. Specimens may result from incisional biopsy and/or surgical resection and/or blood. Whole blood is taken for germinal analysis; 2. Age \>=18 years; 3. Patients must understand and provide written informed consent; 4. Life expectancy \>3 months; 5. Presence of biological material from resection and blood considered sufficient by quality and quantity to proceed to molecular characterisation in the opinion of the Investigator Principal Investigator; 6. Presence of available and accessible clinical and histopathological data. Exclusion Criteria: 1. Refusal of informed consent; 2. Uncooperative patients; 3. Presence of other neoplastic diseases in the last 5 years; 4. Pregnant and/or breastfeeding women
Where this trial is running
Aviano, Pordenone and 2 other locations
- Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS — Aviano, Pordenone, Italy (Recruiting)
- Iov — Padova, Italy (Recruiting)
- Azienda Sanitaria Universitaria Friuli Centrale (ASUFC — Udine, Italy (Recruiting)
Study contacts
- Principal investigator: Giuseppe Toffoli — Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
- Study coordinator: Giuseppe Toffoli
- Email: gtoffoli@cro.it
- Phone: 0434 659 612
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.